Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could less heart screening be safer for kidney transplant patients?

NCT ID NCT03674307

Knowledge-focused Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial investigates whether kidney transplant candidates on dialysis can safely skip routine heart screening after being placed on the waiting list. Participants are randomly assigned to either no further screening or regular annual screening for hidden coronary artery disease. The study compares rates of major cardiac events like heart attacks and cardiac death between the two groups. If no screening proves non-inferior, it could change standard care and reduce unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If skipping routine heart screening proves safe, it could simplify care for kidney transplant candidates and reduce unnecessary tests.
What could go wrong
This is a large trial, but it only tests a screening strategy, not a treatment. The results may not apply to all patients, and there is a risk that less screening could miss hidden heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3,306 people

The number who actually took part.

Started

Dec 2018

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. adults aged 18 years of age or older 2. Dialysis-dependent kidney failure and currently being assessed for OR active on the kidney transplant waiting list 3. expected to require further screening for CAD prior to transplantation (by current standard of care); 4. able to give consent; 5. anticipated to undergo transplantation more than 12 months from date of enrolment Exclusion Criteria: 1. patients with signs or symptoms suggestive of uncontrolled cardiac disease such as unstable coronary syndromes, decompensated heart failure, uncontrolled arrhythmia, and severe valvular heart disease; 2. patients who "on-hold" for transplantation due to a medical problem; 3. patients with other solid organ transplants; 4. multi-organ transplant candidates (e.g. kidney-pancreas transplant candidates); 5. patients with planned living donor transplant; 6. patients unable to give consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic kidney disease dialysis disequilibrium syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Dialysis related complication End stage renal disease Kidney transplantation

Contacts and locations

Locations

  • Barts Health NHS Trust

    London, E1 4UJ, United Kingdom

  • CHU de Quebec-Universite Laval's L'Hotel-Dieu de Quebec

    Laval, Quebec, Canada

  • Charité Universitätsmedizin

    Berlin, Germany

  • Dalhousie University

    Halifax, Nova Scotia, B3H 1V8, Canada

  • Epsom and St Helier University Hospitals NHS Trust

    Carshalton, SM5 1AA, United Kingdom

  • King's College Hospital NHS Foundation Trust

    Brixton, SW9 8RR, United Kingdom

  • Kingston Health Science Centre

    Kingston, Ontario, Canada

  • London Health Science Centre

    London, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • St George's University Hospital NHS Trust Foundation

    London, United Kingdom

  • St Michael's Hospital

    Toronto, Ontario, Canada

  • St. Joseph's Healthcare

    Hamilton, Ontario, L8N 4A6, Canada

  • St. Paul's Hospital, University of Saskatchewan

    Saskatoon, Saskatchewan, Canada

  • Sussex Brighton R&D

    Brighton, BN2 1ES, United Kingdom

  • The George Washington University

    Washington D.C., District of Columbia, 20052, United States

  • The Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 7W9, Canada

  • Universite de Montreal, Hopital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

  • University Health Network

    Toronto, Ontario, M5G 2N2, Canada

  • University of Alberta

    Edmonton, Alberta, Canada

  • University of Arizona

    Tucson, Arizona, 85724, United States

  • University of British Columbia

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • University of Montreal, Maisonneuve-Rosemont Hospital

    Montreal, Quebec, H1T 2M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.